Letter by Rosenstein and Parra Regarding Article, “Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38”

Abstract

To the Editor: In the article by Wiviott et al,1 we read about the use of prasugrel compared with clopidogrel in a subgroup of the original Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38. We have several concerns about this article. First, when interpreting a subgroup analysis from within a larger trial, regardless of whether it is post hoc or prespecified, it is …